Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial

BACKGROUND: The newly discovered coronavirus has turned into coronavirus disease 2019 (COVID-19) pandemic and it rages at an unprecedented rate. Considering the findings of previous studies on the use of Intravenous Immunoglobulin (IVIg) for treating severe H(1)N(1) infection and the satisfying resu...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int Immunopharmacol
Главные авторы: Tabarsi, Payam, Barati, Saghar, Jamaati, Hamidreza, Haseli, Sara, Marjani, Majid, Moniri, Afshin, Abtahian, Zahra, Dastan, Alireza, Yousefian, Sahar, Eskandari, Raha, Saffaei, Ali, Monjazebi, Fatemeh, Vahedi, Abdolbaset, Dastan, Farzaneh
Формат: Artigo
Язык:Inglês
Опубликовано: Published by Elsevier B.V. 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7665876/
https://ncbi.nlm.nih.gov/pubmed/33214093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2020.107205
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы